The road map to oral bioavailability: an industrial perspective. - Wikidata - awgldk - TriplyDB

The road map to oral bioavailability: an industrial perspective.

The road map to oral bioavailability: an industrial perspective.

http://www.wikidata.org/entity/Q36543116

about

Discovery of Novel Imidazo[4,5- b ]pyridines as Potent and Selective Inhibitors of Phosphodiesterase 10A (PDE10A)The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.How to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?Innovative oral spray-dried Idebenone systems to improve patient compliance.Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Lead identification and structure-activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.Targeting tumor hypoxia with 2-nitroimidazole-indocyanine green dye conjugates.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.Inorganic matrices: an answer to low drug solubility problem.Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery.Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2 Design and evaluation of Lumefantrine - Oleic acid self nanoemulsifying ionic complex for enhanced dissolution.Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly.Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.Mass Spectrometry Imaging proves differential absorption profiles of well-characterised permeability markers along the crypt-villus axis Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5).Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human.Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.Solubility and dissolution enhancement strategies: current understanding and recent trends.Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism.

P2860

Q27684392-FD9A640E-1A85-4842-A9FF-3AA35279A8C9 Q30670381-D0D854BE-1BAD-438A-9CAA-E0A4F5B8F316 Q30920065-642999EA-670A-428E-AD5E-FC8396C67ABC Q31021104-E231FFAF-A428-4258-92A8-C2F3F45AEB05 Q33496817-829D636B-CD70-409B-9081-1AD9D150F93D Q33636171-8C3E6087-2D13-480B-8884-31A65948F1F3 Q33694228-9E5B3B93-AC1F-4682-9522-1AB7A6937B69 Q34749181-7D5D9891-AA54-450D-B173-F845D3A5AB6B Q34757166-AAC26597-B644-4B41-AFD5-B1C2D19B140B Q35090956-4A399DEB-D33F-4643-8023-B0988B8369E3 Q35164876-5452DE72-7D05-405B-8BBF-3A32AB912127 Q36909306-D7FB95C5-E904-4C68-B3D7-3755D55DA0FA Q36923843-FF4C63EF-A45D-4DA2-9A0C-A5488044AD23 Q36960535-9E1F2821-9C95-4C64-97B1-B3821FCE6182 Q37069968-F48FA16C-88D3-4464-874A-232241E095CD Q37600381-46ED8B37-AD49-4F05-8AF1-9311A9B65330 Q38051672-29D22EC7-65D7-4A9A-B31B-EF6EBE11B1F1 Q38661732-F90BBDF5-BEA9-4553-8D9E-2FA0DF142C83 Q39785596-3E1911E3-1434-4390-9FF8-6BE36A8FA195 Q40098763-A9BC7AC7-F707-4E77-BF71-2490038A1FC7 Q40226025-D46014C1-350D-4AAB-8D96-AEADD9FB1FBF Q40606599-D2002715-FB36-4388-8C58-E91B3A68111E Q41124799-7C6987AB-50AE-40D9-8662-BECD21295C89 Q41844464-7FB01E0C-852D-438A-A36E-43FB4D984E4A Q46084651-464F8C34-2989-4576-94B5-2D7D79DE552B Q46977325-67CC3289-71F0-419C-85E1-95F72047D2C8 Q48217437-2279C2EF-862B-469A-97BF-9AFEC2D8064F Q51020710-DFEE8879-D46F-44C2-A8BF-70AC2F498070 Q51038149-C61E7349-D371-4312-8987-A2FBA6B71872

P2860

The road map to oral bioavailability: an industrial perspective.

http://www.wikidata.org/entity/Q36543116

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

The road map to oral bioavailability: an industrial perspective.

@ast

The road map to oral bioavailability: an industrial perspective.

@en

type

label

The road map to oral bioavailability: an industrial perspective.

@ast

The road map to oral bioavailability: an industrial perspective.

@en

prefLabel

The road map to oral bioavailability: an industrial perspective.

@ast

The road map to oral bioavailability: an industrial perspective.

@en

P1433

Q36543116-87AAC7C2-622D-4FA6-A1F7-42D8E8705A50

P1476

Q36543116-9B3EAA1F-5700-4BEC-B1B7-B148594A1189

P2093

Q36543116-3D74665F-B550-41C8-9E94-90E7A9D89DBD

Q36543116-6AC370F2-49EE-4D31-BC2A-1E8B729E5B0C

Q36543116-77B6BBDB-2717-4FAE-BD48-54A3D2D6A572

Q36543116-8E01B1B7-6B4E-4190-9908-5E4959E287D0

Q36543116-E0C600B4-DE6B-41C4-B8D4-ED4ADEB27C4C

Q36543116-E37F5ED0-21CE-4B5C-91C5-20E94054B14C

Q36543116-F276F880-E0E3-4C3C-AACB-F694C78AAB2C

Q36543116-FB73FF4F-213C-433B-B842-E3CC79A93F57

P2860

Q36543116-0031AB19-2BF0-4644-97A4-BA6BA4B98DA2

Q36543116-09E16D30-BF04-46DF-B712-9D84EEFE535A

Q36543116-14404569-321C-4926-9BA2-3CC4D5F70382

Q36543116-1851DA69-CA4D-4FF7-B552-FFE00620EB61

Q36543116-2597533E-9058-48A4-BDC5-B746827D5A15

Q36543116-29FA569D-AADC-4996-8990-C2B9B911C720

Q36543116-2A5FE8B6-9F87-4C53-8082-A7862A86C8ED

Q36543116-2CC5D1C8-F7C2-45E2-8E8C-B22A84E4D4A7

Q36543116-2D7EDDCD-0B91-43DC-81EA-2734E7E1AE06

Q36543116-2D92F40E-8C00-448E-95A5-6776B0F34D1E

P304

Q36543116-C7A30183-9B1C-407B-BA7F-DF38FAC2019D

P31

Q36543116-2153BC66-45F2-4239-B0B3-AB9889C3BEEC

P356

Q36543116-B97DAAB6-A168-421F-9F51-4CA8E3F59EDB

P407

Q36543116-36277573-97B0-4738-9E69-DA819D21779E

P433

Q36543116-D893BCD2-9EF3-4E6C-8075-50AE346B3983

P478

Q36543116-B538CD57-43E3-4A6A-BB29-82062E5BCD2A

P577

Q36543116-986BED2D-8F36-4820-8AE6-75589E0E726A

P5875

Q36543116-26E26730-CB07-4140-B05C-19D4022F8275

P698

Q36543116-F74E0539-5C48-43EE-B8C9-620AC918CE14

P356

17425255.2.4.591

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

The road map to oral bioavailability: an industrial perspective.

@en

P2093

Ayman El-Kattan

http://www.w3.org/2001/XMLSchema#string

Chad L Stoner

http://www.w3.org/2001/XMLSchema#string

Linda Hitchingham

http://www.w3.org/2001/XMLSchema#string

Maryanne Naath

http://www.w3.org/2001/XMLSchema#string

Narayanan Surendran

http://www.w3.org/2001/XMLSchema#string

Philip Zocharski

http://www.w3.org/2001/XMLSchema#string

Shobha Bhattachar

http://www.w3.org/2001/XMLSchema#string

V Hayden Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

The price of innovation: new estimates of drug development costs

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highl

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

pH-solubility profiles or organic carboxylic acids and their salts

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.

Drug-like properties and the causes of poor solubility and poor permeability.

Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs.

Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.

P304

591-608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2.4.591

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6927422

http://www.w3.org/2001/XMLSchema#string

P698

16859407

http://www.w3.org/2001/XMLSchema#string